Harmine Hydrochloride Capsules for Diabetes Mellitus
Study Summary
The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.
Treatment Effectiveness
Effectiveness Progress
Other trials for Diabetes Mellitus
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: end of study, at 18 months
Trial Safety
Safety Progress
Other trials for Diabetes Mellitus
Trial Design
1 Treatment Group
Harmine Dose
1 of 1
40 Total Participants · 1 Treatment Group
Primary Treatment: Harmine Hydrochloride Capsules · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Eligibility Criteria
Age 18 - 65 · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.